ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update
Journal of the American College of Radiology · 2023
DOI: 10.1016/j.jacr.2023.02.010 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the American College of Radiology, 2023. Verfasst von Expert Panel on Urological Imaging und 14 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: akino@mskcc.org. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Prostate cancer is second leading cause of death from malignancy after lung cancer in American men. The primary goal during pretreatment evaluation of prostate cancer is disease detection, localization, establishing disease extent (both local and distant), and evaluating aggressiveness, which are the driving factors of patient outcomes such as recurrence and survival. Prostate cancer is typically diagnosed after the recognizing elevated serum prostate-specific antigen level or abnormal digital rectal examination. Tissue diagnosis is obtained by transrectal ultrasound-guided biopsy or MRI-targeted biopsy, commonly with multiparametric MRI without or with intravenous contrast, which has recently been established as standard of care for detecting, localizing, and assessing local extent of prostate cancer. Although bone scintigraphy and CT are still typically used to detect bone and nodal metastases in patients with intermediate- or high-risk prostate cancer, novel advanced imaging modalities including prostatespecific membrane antigen PET/CT and whole-body MRI are being more frequently utilized for this purpose with improved detection rates. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: akino@mskcc.org.
- Research Author, Memorial Sloan Kettering Cancer Center, New York, New York.
- Panel Chair, University of Chicago, Chicago, Illinois.
- Panel Vice-Chair, Duke University Medical Center, Durham, North Carolina.
- Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Commission on Nuclear Medicine and Molecular Imaging.
- University of Minnesota, Minneapolis, Minnesota; Director of Ultrasound M Health Fairview.
Förderung
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Expert Panel on Urological Imaging, Akin, O., Woo, S., Oto, A., Allen, B. C., Avery, R., Barker, S. J., Gerena, M., Halpern, D. J., Gettle, L. M., Rosenthal, S. A., Taneja, S. S., Turkbey, B., Whitworth, P., & Nikolaidis, P. (2023). ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. Journal of the American College of Radiology. https://doi.org/10.1016/j.jacr.2023.02.010
Vancouver
Expert Panel on Urological Imaging, Akin O, Woo S, Oto A, Allen BC, Avery R, et al. ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. Journal of the American College of Radiology. 2023. doi:10.1016/j.jacr.2023.02.010
BibTeX
@article{ExpertPanelonUrologicalImaging2023,
author = {Expert Panel on Urological Imaging, Expert Panel on Urological Imaging and Akin, Oguz and Woo, Sungmin and Oto, Aytekin and Allen, Brian C and Avery, Ryan and Barker, Samantha J and Gerena, Marielia and Halpern, David J and Gettle, Lori Mankowski and Rosenthal, Seth A and Taneja, Samir S and Turkbey, Baris and Whitworth, Pat and Nikolaidis, Paul},
title = {ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update},
journal = {Journal of the American College of Radiology},
year = {2023},
doi = {10.1016/j.jacr.2023.02.010}
}
EUVIMED